RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas. The Company is currently commercializing UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

Medical Devices

Therapeutics

RVL Pharmaceuticals

Brian Markison

Nick Fee

Danielle Scandone

Jd Schaub

Tina Devries

Jarret Miller

James Schaub

Andrew Einhorn

Sales and Business Development

Leadership Team

Finance and Accounting

Human Resources and Talent Management

Legal and Regulatory Affairs

Marketing and Communications